Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens

NCT03901339 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03901339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03901339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
May 8, 2019
Completion date
October 20, 2023
Enrollment
543 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer